癌的细胞免疫疗法是基于对肿瘤宿主全身给予白细胞介素-2(IL-2)和输入由IL-2激活的自体淋巴细胞。目前,正研究外周血液的活性淋巴细胞(活性淋巴因子杀伤细胞,LAK)和肿瘤组织内的淋巴细胞(肿瘤浸润淋巴细胞,TIL)的作用。 LAK的活性是通过IL-2中孵化外周血液淋巴细胞3～4天而产生。通过短期铬释放实验,这些细胞能溶解各种新生和培养的肿瘤,这证明对自体肿瘤组织没有特异性。小鼠的多种致免疫和非致免疫的肿瘤模型,证明了LAK和IL-2能消除肺和肝肿瘤的早期转移。 Cancer cell immunotherapy is based on the systemic administration of interleukin-2 (IL-2) to tumor hosts and the import of autologous lymphocytes activated by IL-2. At present, the role of active lymphocytes (active lymphokine killer cells, LAK) in peripheral blood and lymphocytes (tumor infiltrating lymphocytes, TIL) in tumor tissues is being studied. The activity of LAK is produced by the incubation of peripheral blood lymphocytes in IL-2 for 3 to 4 days. Through short-term chromium release experiments, these cells were able to dissolve a variety of neonatal and cultured tumors, demonstrating no specificity for autologous tumor tissue. Multiple immunogenic and non-immunogenic tumor models in mice demonstrate that LAK and IL-2 can eliminate the early metastasis of lung and liver tumors.